SNSE insider sells 25,000 Sensei Biotherapeutics shares

Sensei Biotherapeutics, Inc. ten percent owner James Peyer reported open-market sales of 25,000 shares of Common Stock.

Rhea-AI Filing Summary

Sensei Biotherapeutics, Inc. ten percent owner James Peyer reported open-market sales of 25,000 shares of Common Stock. The sales occurred on June 1, 2026 in two transactions: 24,524 shares at $20.00 per share and 476 shares at $21.14 per share.

After these transactions, he continued to hold more than 130,000 shares of Common Stock directly. A footnote explains that one reported price reflects a weighted average for trades executed in a range from $20.00 to $21.00, with detailed breakdowns available upon request.

Insights

Equity ownership analyst

Ten percent holder records a moderate net sale but retains a large stake.

Ten percent owner James Peyer reported open-market sales totaling 25,000 shares of Sensei Biotherapeutics Common Stock on June 1, 2026, at prices between $20.00 and $21.14 per share. These are straightforward open-market transactions using code S.

Following the sales, he still holds over 130,000 shares directly, indicating a continuing sizable position. The filing notes a weighted average price within a $20.00–$21.00 range and offers full price breakdowns on request, but does not mention any trading plan or derivatives, so the signal appears limited and routine.

Insider Trade Summary

Net Seller: 25,000 shares

Net Sell 2 txns

Insider Peyer James

Role 10% Owner

Sold 25,000 shs ($501K)

Type	Security	Shares	Price	Value
Sale	Common Stock	24,524	$20.00	$490K
Sale	Common Stock	476	$21.14	$10K

Holdings After Transaction: Common Stock — 130,142 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. The prices sold ranged from $20.00 to $21.00. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Total shares sold: 25,000 shares First sale tranche: 24,524 shares at $20.00/share Second sale tranche: 476 shares at $21.14/share +2 more

5 metrics

Total shares sold 25,000 shares Net open-market sales on June 1, 2026

First sale tranche 24,524 shares at $20.00/share Common Stock open-market sale

Second sale tranche 476 shares at $21.14/share Common Stock open-market sale

Shares held after transaction 130,142 shares Direct Common Stock holding following one reported sale

Price range referenced $20.00–$21.00 Weighted average sale price range in footnote

Key Terms

open-market sale, ten percent owner, weighted average price

3 terms

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

ten percent owner regulatory

""is_ten_percent_owner": 1"

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did James Peyer report for Sensei Biotherapeutics (SNSE)?

James Peyer reported selling 25,000 shares of Sensei Biotherapeutics Common Stock in open-market transactions. The sales occurred on June 1, 2026, and were split into two trades at prices of $20.00 and $21.14 per share, respectively.

At what prices did James Peyer sell SNSE shares in this Form 4 filing?

He sold 24,524 Sensei Biotherapeutics shares at $20.00 per share and 476 shares at $21.14 per share. A footnote states one reported price is a weighted average within a $20.00 to $21.00 trading range, with detailed breakdowns available on request.

How many Sensei Biotherapeutics (SNSE) shares did James Peyer sell in total?

He sold a total of 25,000 shares of Sensei Biotherapeutics Common Stock. The Form 4 transaction summary classifies this as net-sell activity, with two separate open-market sale transactions reported for the same date and no corresponding purchases or derivative exercises.

Does James Peyer still hold SNSE shares after the reported sales?

Yes. After the reported open-market sales, the Form 4 shows that James Peyer continues to hold more than 130,000 shares of Sensei Biotherapeutics Common Stock directly. This indicates he remains a significant shareholder despite the 25,000-share net sale.

What does the weighted average price footnote mean in the SNSE Form 4?

The footnote explains that the reported sale price is a weighted average of multiple trades executed between $20.00 and $21.00. It states the reporting person will provide full details on the number of shares sold at each specific price within this range upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 05:20 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peyer James

(Last) (First) (Middle)

228 PARK AVENUE S.

#66643

(Street)

NEW YORK NEW YORK 10003

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sensei Biotherapeutics, Inc. [ SNSE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)	X	Other (specify below)
			See remarks below

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		S		24,524	D	$20(1)	130,618	D
Common Stock	06/01/2026		S		476	D	$21.14	130,142	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. The prices sold ranged from $20.00 to $21.00. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

	/s/ James Peyer	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)